Omada Health, Inc. $OMDA is Liberty Street Advisors Inc.'s 4th Largest Position

Key Points

• Liberty Street Advisors cut its Omada Health (OMDA) stake by 50.6% in Q4 to 219,800 shares, making OMDA its fourth-largest holding at about 5.8% of the portfolio (≈$3.47M).
• Major institutions are active: Cigna established a new ≈$76.2M stake and Vanguard increased its position by 642.8% to 482,790 shares (≈$10.7M), indicating notable institutional interest.
• Omada beat quarterly EPS estimates (reported $0.08 vs. -$0.04 est.), trades around $12 with a market cap of ≈$714M, and carries a consensus analyst rating of "Moderate Buy" with a $22 price target.

Liberty Street Advisors Inc. lowered its position in Omada Health, Inc. (NASDAQ:OMDA - Free Report) by 50.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 219,800 shares of the company's stock after selling 225,000 shares during the quarter. Omada Health makes up approximately 5.8% of Liberty Street Advisors Inc.'s portfolio, making the stock its 4th biggest position. Liberty Street Advisors Inc. owned about 0.38% of Omada Health worth $3,468,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of OMDA. Cigna Investments Inc. New bought a new stake in Omada Health in the third quarter valued at approximately $76,161,000. Perceptive Advisors LLC bought a new stake in Omada Health in the second quarter valued at approximately $44,402,000. Divisadero Street Capital Management LP bought a new stake in Omada Health in the third quarter valued at approximately $30,510,000. BIT Capital GmbH bought a new stake in Omada Health in the third quarter valued at approximately $13,639,000. Finally, Vanguard Group Inc. lifted its position in Omada Health by 642.8% in the third quarter. Vanguard Group Inc. now owns 482,790 shares of the company's stock valued at $10,674,000 after purchasing an additional 417,790 shares during the last quarter.

Insiders Place Their Bets

In other Omada Health news, President Wei-Li Shao sold 2,829 shares of the stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $12.71, for a total value of $35,956.59. Following the completion of the transaction, the president owned 328,850 shares in the company, valued at approximately $4,179,683.50. This represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Steven L. Cook sold 1,884 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $13.94, for a total value of $26,262.96. Following the completion of the transaction, the chief financial officer owned 200,512 shares of the company's stock, valued at approximately $2,795,137.28. This trade represents a 0.93% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 8,776 shares of company stock worth $120,483.

Omada Health Trading Up 6.2%

OMDA opened at $12.12 on Tuesday. The stock has a fifty day simple moving average of $12.68 and a two-hundred day simple moving average of $16.87. The company has a market cap of $714.11 million and a price-to-earnings ratio of -71.29. Omada Health, Inc. has a 12-month low of $10.28 and a 12-month high of $28.40.

Omada Health (NASDAQ:OMDA - Get Free Report) last posted its quarterly earnings data on Thursday, March 5th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.12. The firm had revenue of $75.85 million during the quarter.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. The Goldman Sachs Group lowered their price objective on Omada Health from $26.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, April 9th. Wall Street Zen upgraded Omada Health from a "hold" rating to a "buy" rating in a research report on Saturday, March 14th. Evercore reiterated an "outperform" rating and issued a $15.00 price objective on shares of Omada Health in a research report on Wednesday, April 8th. Canaccord Genuity Group lowered their price objective on Omada Health from $28.00 to $22.00 and set a "buy" rating for the company in a research report on Friday, March 6th. Finally, Morgan Stanley decreased their target price on Omada Health from $32.00 to $30.00 and set an "overweight" rating for the company in a report on Friday, March 6th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $22.00.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.

Want to see what other hedge funds are holding OMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omada Health, Inc. (NASDAQ:OMDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.